1
|
Akhtar N and Bansal JG: Risk factors of
lung cancer in nonsmoker. Curr Probl Cancer. 41:328–339.
2017.PubMed/NCBI View Article : Google Scholar
|
2
|
Herbst RS, Morgensztern D and Boshoff C:
The biology and management of non-small cell lung cancer. Nature.
553:446–454. 2018.PubMed/NCBI View Article : Google Scholar
|
3
|
Hirsch FR, Scagliotti GV, Mulshine JL,
Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current
therapies and new targeted treatments. Lancet. 389:299–311.
2017.PubMed/NCBI View Article : Google Scholar
|
4
|
Deng D and Shah K: TRAIL of hope meeting
resistance in cancer. Trends Cancer. 6:989–1001. 2020.PubMed/NCBI View Article : Google Scholar
|
5
|
Middleton G, Fletcher P, Popat S, Savage
J, Summers Y, Greystoke A, Gilligan D, Cave J, O'Rourke N, Brewster
A, et al: The National lung matrix trial of personalized therapy in
lung cancer. Nature. 583:807–812. 2020.PubMed/NCBI View Article : Google Scholar
|
6
|
McConnell DD, Carr SB and Litofsky NS:
Potential effects of nicotine on glioblastoma and
chemoradiotherapy: A review. Expert Rev Neurother. 19:545–555.
2019.PubMed/NCBI View Article : Google Scholar
|
7
|
Cheng FJ, Chen CH, Tsai WC, Wang BW, Yu
MC, Hsia TC, Wei YL, Hsiao YC, Hu DW, Ho CY, et al: Cigarette
smoke-induced LKB1/AMPK pathway deficiency reduces EGFR TKI
sensitivity in NSCLC. Oncogene. 40:1162–1175. 2021.PubMed/NCBI View Article : Google Scholar
|
8
|
Liang WC, Ren JL, Wong CW, Chan SO, Waye
MM, Fu WM and Zhang JF: LncRNA-NEF antagonized epithelial to
mesenchymal transition and cancer metastasis via cis-regulating
FOXA2 and inactivating Wnt/β-catenin signaling. Oncogene.
37:1445–1456. 2018.PubMed/NCBI View Article : Google Scholar
|
9
|
Liu MY, Li XQ, Gao TH, Cui Y, Ma N, Zhou Y
and Zhang GJ: Elevated HOTAIR expression associated with cisplatin
resistance in non-small cell lung cancer patients. J Thorac Dis.
8:3314–3322. 2016.PubMed/NCBI View Article : Google Scholar
|
10
|
Yang Z, Li Q, Zheng X and Xie L: Long
Noncoding RNA small nucleolar host gene: A potential therapeutic
target in urological cancers. Front Oncol.
11(638721)2021.PubMed/NCBI View Article : Google Scholar
|
11
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
12
|
Tu H and Costa M: XIAP's profile in human
cancer. Biomolecules. 10(1493)2020.PubMed/NCBI View Article : Google Scholar
|
13
|
Zimta AA, Tigu AB, Braicu C, Stefan C,
Ionescu C and Berindan-Neagoe I: An emerging class of long
Non-coding RNA with oncogenic role arises from the snoRNA host
genes. Front Oncol. 10(389)2020.PubMed/NCBI View Article : Google Scholar
|
14
|
Qin Y, Sun W, Wang Z, Dong W, He L, Zhang
T and Zhang H: Long Non-Coding small nucleolar RNA host genes
(SNHGs) in endocrine-related cancers. Onco Targets Ther.
13:7699–7717. 2020.PubMed/NCBI View Article : Google Scholar
|
15
|
Yang T and Shen J: Small nucleolar RNAs
and SNHGs in the intestinal mucosal barrier: Emerging insights and
current roles. J Adv Res: Jun 11, 2022 (Epub ahead of print).
|
16
|
Dasgupta P, Kinkade R, Joshi B, Decook C,
Haura E and Chellappan S: Nicotine inhibits apoptosis induced by
chemotherapeutic drugs by up-regulating XIAP and survivin. Proc
Natl Acad Sci USA. 103:6332–6337. 2006.PubMed/NCBI View Article : Google Scholar
|
17
|
Jin Z, Gao F, Flagg T and Deng X: Nicotine
induces multi-site phosphorylation of Bad in association with
suppression of apoptosis. J Biol Chem. 279:23837–23844.
2004.PubMed/NCBI View Article : Google Scholar
|
18
|
Zhang J, Kamdar O, Le W, Rosen GD and
Upadhyay D: Nicotine induces resistance to chemotherapy by
modulating mitochondrial signaling in lung cancer. Am J Respir Cell
Mol Biol. 40:135–146. 2009.PubMed/NCBI View Article : Google Scholar
|
19
|
Riedl SJ, Renatus M, Schwarzenbacher R,
Zhou Q, Sun C, Fesik SW, Liddington RC and Salvesen GS: Structural
basis for the inhibition of caspase-3 by XIAP. Cell. 104:791–800.
2001.PubMed/NCBI View Article : Google Scholar
|
20
|
Von Karstedt S, Montinaro A and Walczak H:
Exploring the TRAILs less travelled: TRAIL in cancer biology and
therapy. Nat Rev Cancer. 17:352–366. 2017.PubMed/NCBI View Article : Google Scholar
|
21
|
Jost PJ, Grabow S, Gray D, McKenzie MD,
Nachbur U, Huang DC, Bouillet P, Thomas HE, Borner C, Silke J, et
al: XIAP discriminates between type I and type II FAS-induced
apoptosis. Nature. 460:1035–1039. 2009.PubMed/NCBI View Article : Google Scholar
|
22
|
Jost PJ and Vucic D: Regulation of cell
death and immunity by XIAP. Cold Spring Harb Perspect Biol.
12(a036426)2020.PubMed/NCBI View Article : Google Scholar
|
23
|
Eberle J: Countering TRAIL resistance in
melanoma. Cancers (Basel). 11(656)2019.PubMed/NCBI View Article : Google Scholar
|
24
|
Vogler M, Walczak H, Stadel D, Haas TL,
Genze F, Jovanovic M, Bhanot U, Hasel C, Möller P, Gschwend JE, et
al: Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis
and antitumor activity in preclinical models of pancreatic
carcinoma. Cancer Res. 69:2425–2434. 2009.PubMed/NCBI View Article : Google Scholar
|
25
|
Stadel D, Mohr A, Ref C, MacFarlane M,
Zhou S, Humphreys R, Bachem M, Cohen G, Möller P, Zwacka RM, et al:
TRAIL-induced apoptosis is preferentially mediated via TRAIL
receptor 1 in pancreatic carcinoma cells and profoundly enhanced by
XIAP inhibitors. Clin Cancer Res. 16:5734–5749. 2010.PubMed/NCBI View Article : Google Scholar
|